LNSR
LENSAR, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.58
+4.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 60.3M | 58.4M | 53.5M | 42.2M | 35.4M |
| Cost of Revenue | 31.4M | 31.3M | 27.6M | 21.1M | 15.4M |
| Gross Profit | 28.9M | 27.1M | 25.9M | 21.1M | 20.0M |
| Operating Expenses | |||||
| R&D Expense | 5.3M | 5.6M | 5.3M | 6.1M | 11.8M |
| SG&A Expense | 31.0M | 45.2M | 26.5M | 26.1M | 27.2M |
| General & Admin Expense | 8.7M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 687.0K | 921.0K | 4.7M | 1.1M | 1.1M |
| Total Operating Expenses | 37.0M | 51.7M | 36.5M | 33.3M | 40.1M |
| Cost and Expenses | 68.4M | 83.0M | 64.2M | 54.4M | 55.5M |
| Operating Income (EBIT) | (8.1M) | (24.6M) | (10.7M) | (12.2M) | (20.2M) |
| Non-Operating | |||||
| Interest Income | 40.0K | 91.0K | 103.0K | 85.0K | 17.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 40.0K | 91.0K | 103.0K | 85.0K | 17.0K |
| Other Non-Op Income/Expense | 42.8M | (9.7M) | (20.7M) | (2.2M) | 263.0K |
| Non-Operating Income (excl Interest) | (40.0M) | 9.7M | (3.7M) | 2.2M | (263.0K) |
| EBT (Pre-Tax Income) | 34.7M | (34.3M) | (31.4M) | (14.4M) | (19.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 34.7M | (34.3M) | (31.4M) | (14.4M) | (19.9M) |
| Earnings from Cont. Ops | 34.7M | (34.3M) | (31.4M) | (14.4M) | (19.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 16.0M | (34.3M) | (31.4M) | (14.4M) | (19.9M) |
| Per Share | |||||
| Basic EPS | $1.27 | ($2.87) | ($2.73) | ($1.31) | ($1.96) |
| Diluted EPS | ($0.33) | ($2.87) | ($2.73) | ($1.31) | ($1.96) |
| Revenue Per Share | $4.90 | $4.89 | $4.64 | $3.84 | $3.48 |
| Shares | |||||
| Basic Shares Outstanding | 12.3M | 12.0M | 11.5M | 11.0M | 10.2M |
| Diluted Shares Outstanding | 23.0M | 12.0M | 11.5M | 11.0M | 10.2M |
| Profitability Metrics | |||||
| EBITDA | 35.6M | (29.8M) | (3.0M) | (10.9M) | (16.5M) |
| D&A | 3.7M | 4.5M | 3.9M | 3.5M | 3.4M |
| EBIT | 31.9M | (34.3M) | (6.9M) | (14.4M) | (19.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026